the stock appears undervalued based on its Fair Value estimates, suggesting potential upside for investors. This comprehensive analysis examines Pfizer’s current position, recent performance ...

the stock appears undervalued based on its Fair Value estimates, suggesting potential upside for investors. This comprehensive analysis examines Pfizer’s current position, recent performance, and ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

This is where InvestingPro’s powerful stock screener comes in. Among its many pre-built tools, the “ Cash is King ” screener stands out for investors who prioritize financial strength. It identifies ...

Many investors turn to Benjamin Graham's so-called “Graham number” to calculate the fair price of a stock. The Graham number ...

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar ...

Pfizer (PFE 0.77%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Bispecific anti-PD1/VEGF remains one of the hottest topics in the oncology field. Click here for a detailed analysis.

The stock's fall snapped a four-day winning streak.